Logo image of PMN

PROMIS NEUROSCIENCES INC (PMN) Stock Fundamental Analysis

NASDAQ:PMN - Nasdaq - CA74346M4065 - Common Stock - Currency: USD

0.48  -0.01 (-1.03%)

Fundamental Rating

3

Taking everything into account, PMN scores 3 out of 10 in our fundamental rating. PMN was compared to 558 industry peers in the Biotechnology industry. While PMN seems to be doing ok healthwise, there are quite some concerns on its profitability. PMN has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PMN had positive earnings in the past year.
In the past year PMN has reported a negative cash flow from operations.
PMN had negative earnings in each of the past 5 years.
In the past 5 years PMN always reported negative operating cash flow.
PMN Yearly Net Income VS EBIT VS OCF VS FCFPMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

PMN has a Return On Assets of -6.84%. This is amongst the best in the industry. PMN outperforms 86.38% of its industry peers.
PMN's Return On Equity of -9.86% is amongst the best of the industry. PMN outperforms 88.17% of its industry peers.
Industry RankSector Rank
ROA -6.84%
ROE -9.86%
ROIC N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PMN Yearly ROA, ROE, ROICPMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PMN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMN Yearly Profit, Operating, Gross MarginsPMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for PMN has been increased compared to 1 year ago.
PMN has more shares outstanding than it did 5 years ago.
PMN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PMN Yearly Shares OutstandingPMN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PMN Yearly Total Debt VS Total AssetsPMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -11.92, we must say that PMN is in the distress zone and has some risk of bankruptcy.
PMN has a worse Altman-Z score (-11.92) than 77.42% of its industry peers.
PMN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.92
ROIC/WACCN/A
WACCN/A
PMN Yearly LT Debt VS Equity VS FCFPMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

PMN has a Current Ratio of 3.36. This indicates that PMN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.36, PMN is doing worse than 61.11% of the companies in the same industry.
A Quick Ratio of 3.36 indicates that PMN has no problem at all paying its short term obligations.
PMN's Quick ratio of 3.36 is in line compared to the rest of the industry. PMN outperforms 40.32% of its industry peers.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 3.36
PMN Yearly Current Assets VS Current LiabilitesPMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.01% over the past year.
EPS 1Y (TTM)95.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.44% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.81%
EPS Next 2Y20.27%
EPS Next 3Y19.52%
EPS Next 5Y11.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMN Yearly Revenue VS EstimatesPMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2028 2029 2030 50M 100M 150M 200M 250M
PMN Yearly EPS VS EstimatesPMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

PMN is valuated cheaply with a Price/Earnings ratio of 6.86.
Based on the Price/Earnings ratio, PMN is valued cheaply inside the industry as 98.21% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.91, PMN is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for PMN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 6.86
Fwd PE N/A
PMN Price Earnings VS Forward Price EarningsPMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMN Per share dataPMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PMN's earnings are expected to grow with 19.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y20.27%
EPS Next 3Y19.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROMIS NEUROSCIENCES INC

NASDAQ:PMN (6/25/2025, 1:27:05 PM)

0.48

-0.01 (-1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners28.48%
Inst Owner Change-4.62%
Ins Owners7.3%
Ins Owner Change0%
Market Cap15.69M
Analysts85.71
Price Target5.78 (1104.17%)
Short Float %0.71%
Short Ratio3.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.83%
Min EPS beat(2)-73.27%
Max EPS beat(2)92.93%
EPS beat(4)3
Avg EPS beat(4)180.45%
Min EPS beat(4)-73.27%
Max EPS beat(4)694.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.05%
PT rev (3m)-27.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.69%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6.86
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)0.07
EY14.58%
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.29
TBVpS0.29
PEG (NY)0.07
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.84%
ROE -9.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 3.36
Altman-Z -11.92
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)6.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.53%
EPS Next Y94.81%
EPS Next 2Y20.27%
EPS Next 3Y19.52%
EPS Next 5Y11.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-96.21%
EBIT Next 3Y-18.55%
EBIT Next 5Y33.13%
FCF growth 1Y-83.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.34%
OCF growth 3YN/A
OCF growth 5YN/A